HPS3/TIMI55 : Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
• Possible re-emergence of CETP inhibitors. Previous CETP clinical trials demonstrated either neutral or adverse cardiovascular effects.
• Anacetrapib could be an effective add-on therapy for high-risk patients (established ASCVD) who do not attain their LDL targets on statin therapy or are statin intolerant
HPS3/TIMI55–REVEAL Collaborative Group, Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, Wiviott SD, Cannon CP, Braunwald E, Sammons E, Landray MJ. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. N Engl J Med. 2017 Sep 28;377(13):1217-1227.